Search results for "Leukaemia"

showing 10 items of 65 documents

Association of childhood leukaemia with factors related to the immune system

1999

The childhood peak of common acute lymphoblastic leukaemia has been proposed as being a rare response to delayed exposure to a common infection. In this context, factors related to the child’s immune system are of special interest. Information on such factors was obtained in a recent German case-control study comprising more than 1000 children with acute leukaemia. Neither being the first-born child, nor a short duration of breastfeeding, indicators of a deficit in viral contacts during infancy or the number of infectious diseases, were significant risk factors. We observed a strong association with fewer routine immunizations with a 3.2-fold increase for those children getting less than fo…

MaleCancer ResearchPediatricsmedicine.medical_specialtyAllergyAdolescentcase-control studyBreastfeedingContext (language use)Infectionschildhood leukaemiaRisk FactorsGermanyHypersensitivitymedicineHumansRisk factorChildbusiness.industryIncidenceIncidence (epidemiology)Infant NewbornCase-control studyInfantRegular ArticlePrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseimmune systemOncologyEl NiñoReporting biasCase-Control StudiesChild PreschoolFemalebusinessBritish Journal of Cancer
researchProduct

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

2015

Treatment of acute promyelocytic leukaemia (APL) with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is highly effective first-line therapy, although approximately 5-10% of patients relapse. Tamibarotene is a synthetic retinoid with activity in APL patients who relapse after chemotherapy and ATRA, but has not been studied in relapse after treatment with ATO and ATRA. We report on a phase II study of tamibarotene in adult patients with relapsed or refractory APL after treatment with ATRA and ATO (n = 14). Participants were treated with tamibarotene (6 mg/m(2) /d) during induction and for up to six cycles of consolidation. The overall response rate was 64% (n = 9), the rate of comp…

MaleOncogene Proteins Fusionmedicine.medical_treatmentDrug ResistancePhases of clinical researchSalvage therapyKaplan-Meier EstimatePharmacologyGastroenterologyBenzoatesArsenicalschemistry.chemical_compoundLeukemia Promyelocytic AcuteRecurrenceAntineoplastic Combined Chemotherapy ProtocolsMedicineArsenic trioxidePromyelocyticOncogene ProteinsTumorLeukemiaRemission InductionHematopoietic Stem Cell TransplantationCell DifferentiationOxidesclinical trialHematologyMiddle AgedCombined Modality Therapyall-trans retinoic acidarsenic trioxideLeukemiaCardiovascular DiseasesFemalemedicine.drugAdultmedicine.medical_specialtyTetrahydronaphthalenesAcute promyelocytic leukaemia; all-trans retinoic acid; arsenic trioxide; clinical trial; tamibarotene; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers Tumor; Cardiovascular Diseases; Cell Differentiation; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Drug Resistance Neoplasm; Febrile Neutropenia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia Promyelocytic Acute; Male; Middle Aged; Oncogene Proteins Fusion; Oxides; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; TretinoinAntineoplastic AgentsTretinoinAcuteArticleDisease-Free SurvivalTretinoinInternal medicineBiomarkers TumorHumansFusionneoplasmsAgedFebrile NeutropeniaSalvage TherapyChemotherapybusiness.industrymedicine.diseasetamibaroteneAcute promyelocytic leukaemiaConsolidation ChemotherapychemistryDrug Resistance NeoplasmNeoplasmTamibarotenebusinessSettore MED/15 - Malattie del SangueFebrile neutropeniaBiomarkers
researchProduct

Lymphoproliferative disorders in Sotos syndrome: Observation of two cases

1996

Sotos syndrome is included among the overgrowth disorders, most of which have an increased risk of neoplasms. Sotos syndrome does not appear to be related to a specific tumor type, but rather to the development of solid tumors of ectodermal or mesodermal origin in general. We report on two Sotos syndrome patients who developed a non-Hodgkin lymphoma and an acute lymphoblastic leukaemia, respectively. Our experience suggests that there may exist a high frequency of lymphoproliferative disorders in Sotos syndrome, and points out the importance of a long-term follow-up of Sotos syndrome patients, to detect a possible neoplastic evolution. ©1996 Wiley-Liss, Inc.

MalePathologymedicine.medical_specialtyLymphoproliferative disordersOvergrowth syndromeshemic and lymphatic diseasesmedicineHumansAbnormalities MultipleTumor typeSotos syndromeGrowth DisordersGenetics (clinical)Sotos syndromebusiness.industrySkullBrainSyndromemedicine.diseasePhenotypeLymphoproliferative DisordersLymphomaIncreased riskEl NiñoChild PreschoolLymphoblastic leukaemiabusinessAmerican Journal of Medical Genetics
researchProduct

Air pollution and childhood leukaemia: a nationwide case-control study in Italy

2013

Objectives Leukaemia is the most common cancer in children, but its aetiology is still poorly understood. We tested the hypothesis that traffic-related air pollution is associated with paediatric leukaemia because of chronic exposure to several potential carcinogens. Methods The Italian SETIL study (Study on the aetiology of lymphohematopoietic malignancies in children) was conducted in 14 Italian regions. All incident cases of leukaemia in children aged ≤10 years from these regions (period 1998–2001) were eligible for enrolment. Two controls per case, matched on birth date, gender and region of residence were randomly selected from the local population registries. Exposure assessment at bi…

MalePediatricsAir pollutionNO2Land use Regression ModelLogistic regressionmedicine.disease_causeEconomicaResidence CharacteristicsUSE REGRESSION-MODELSMedicineChildChildrenVehicle EmissionsGeneral Environmental ScienceUSE REGRESSION-MODELS RESIDENTIAL TRAFFIC DENSITY MAGNETIC-FIELDS POOLED ANALYSIS RISK-FACTOR CANCER EXPOSURE CHILDREN NO2 ASSOCIATIONLeukemiaIncidenceIncidence (epidemiology)ASSOCIATIONCANCERChildhood leukaemiaItalyChild PreschoolFemaleCase-Control StudieHumanmedicine.medical_specialtySocio-culturaleMAGNETIC-FIELDSPOOLED ANALYSISRISK-FACTORAir PollutionOccupational ExposureEnvironmental healthTraffic IndicatorHumansEXPOSURERESIDENTIAL TRAFFIC DENSITYExposure assessmentVehicle Emissionbusiness.industryPublic Health Environmental and Occupational HealthCase-control studyAmbientaleInfantCarcinogens EnvironmentalAutomobileCase-Control StudiesResidence CharacteristicDispersion ModelEtiologyGeneral Earth and Planetary SciencesParticulate MatterResidencebusinessAutomobilesOccupational and Environmental Medicine
researchProduct

SETIL: Italian multicentric epidemiological case–control study on risk factors for childhood leukaemia, non hodgkin lymphoma and neuroblastoma: study…

2014

Background Aetiology of childhood leukaemia and childhood neoplasm is poorly understood. Information on the prevalence of risk factors in the childhood population is limited. SETIL is a population based case–control study on childhood leukaemia, conducted with two companion studies on non-Hodgkin Lymphoma (NHL) and neuroblastoma. The study relies on questionnaire interviews and 50 Hz magnetic field (ELF-MF) indoor measurements. This paper discusses the SETIL study design and includes descriptive information. Methods The study was carried out in 14 Italian regions (78.3% of Italian population aged 0–10). It included leukaemia, NHL and neuroblastoma cases incident in 0–10 year olds in 1998–20…

MalePediatricsPassive smokingLymphomaEpidemiologyNon hogdkin lymphomamedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataNeuroblastomaEconomicahemic and lymphatic diseasesEpidemiologyPrevalencerisk factorsLeukaemiaChildeducation.field_of_studyIncidence (epidemiology)IncidenceLymphoma Non-Hodgkinnon hodgkin lymphoma and neuroblastomaEnvironmental exposureItalyChild PreschoolPopulation studyFemaleHumanmedicine.medical_specialtyPopulationNon-HodgkinSocio-culturalestudy populationRisk Assessmentchildhood leukaemiamedicineHumanseducationPreschoolPregnancybusiness.industryResearchrisk factors; childhood leukaemia; non hodgkin lymphoma and neuroblastoma; study populationCase-control studyInfant NewbornAmbientaleInfantEnvironmental Exposuremedicine.diseaseNewbornbusiness
researchProduct

Incidence, time trends and regional variation of childhood leukaemia in Germany and Europe.

2008

This paper presents data on the German and Europe-wide incidence, time trends and regional variations of childhood leukaemia. Data were provided by the German Childhood Cancer Registry (GCCR), a population-based cancer registry recording all cases of malignant diseases in children under 15 y of age residing in Germany and by the Automated Childhood Cancer Information System (ACCIS) co-ordinated at International Agency for Research on Cancer, Lyon, that combines and evaluates data from several European population-based cancer registries. The incidence of leukaemia (44.0 per million) has increased in Europe as well as in Germany in the last decades (0.6% annually on average). Germany shows no…

MalePediatricsmedicine.medical_specialtyAdolescentPopulationDisease OutbreaksGermanGermanymedicineHumansRadiology Nuclear Medicine and imagingRegistrieseducationChildChildhood Cancer Registryeducation.field_of_studyRadiationLeukemiaRadiological and Ultrasound TechnologyIncidence (epidemiology)IncidencePublic Health Environmental and Occupational HealthInfant NewbornCancerInfantGeneral Medicinemedicine.diseaselanguage.human_languageChildhood leukaemiaCancer registryEuropeGeographyRegional variationChild PreschoollanguageFemaleDemographyRadiation protection dosimetry
researchProduct

Hepatitis B virus reactivation and alemtuzumab therapy

2005

Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immmunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab the…

MaleSettore MED/07 - Microbiologia E Microbiologia ClinicaHepatitis B virusHBsAgCD52Antibodies Neoplasmmedicine.medical_treatmenthepatitis B viruAntibodies Monoclonal Humanizedmedicine.disease_causeCampath-1HSettore MED/15 - Malattie Del SanguemedicineHumansAlemtuzumabImmunosuppression TherapyHepatitisHepatitis B virusSettore MED/12 - GastroenterologiaHepatitis B Surface Antigensbusiness.industryacute hepatitiAntibodies Monoclonalvirus diseasesLamivudineImmunosuppressionHematologyGeneral MedicineMiddle AgedHepatitis BHepatitis Bmedicine.diseaseLeukemia Lymphocytic Chronic B-Celldigestive system diseasesLamivudineDNA ViralImmunologyReverse Transcriptase InhibitorsAlemtuzumabFemaleVirus Activationbusinesschronic lymphocytic leukaemiamedicine.drugEuropean Journal of Haematology
researchProduct

Massive pulmonary embolism in a young boy with T-cell leukaemia. Successful thrombolytic therapy by recombinant tissue plasminogen activator (rtPA).

2014

SummaryAcute pulmonary embolism (PE) is a serious complication in association with malignant diseases. We describe the successful treatment of PE applying a systemic thrombolytic therapy in a 4-year-old boy with acute lymphoblastic leukaemia.The thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) 0.1 mg/ kg bodyweight per hour for six hours was continued for six days without important side effects. In particular no bleeding complications were observed. Computed tomography with contrast revealed a remarkable regression of the central PE. Without further delays the chemotherapy was resumed.

Malemedicine.medical_specialtyLeukemia T-Cellmedicine.medical_treatmentComputed tomographyFibrinolytic AgentsmedicineHumansRecombinant tissue plasminogen activatorChemotherapymedicine.diagnostic_testbusiness.industryAnticoagulantsHematologyHeparin Low-Molecular-Weightmedicine.diseaseRecombinant ProteinsSurgeryPulmonary embolismTreatment OutcomeChild PreschoolTissue Plasminogen ActivatorLymphoblastic leukaemiaDrug Therapy CombinationbusinessComplicationPulmonary EmbolismT cell leukaemiaHamostaseologie
researchProduct

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.

2009

OBJECTIVES: Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. METHODS: Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified inten…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaAspergillosisGastroenterologyTransplantation Autologouschemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultCaspofunginInternal medicineClinical endpointmedicineAspergillosisHumansPharmacology (medical)Survival rateSurvival analysisAgedPharmacologyAged 80 and overSurrogate endpointbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationAcute Leukaemia; Fungal Infections; Echinocandins; Bone-Marrow-Transplantation; Stem-Cell Transplants; Mycoses Study-Group; Fungal-Infections; Prognostic-Factors; European-Organization; Amphotericin-B; Consensus; Epidemiology; VoriconazoleInfectious DiseasesTreatment OutcomechemistryHematologic NeoplasmsFemaleCaspofunginbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Infezione da HHV8 e leucemia linfoblastica acuta in età pediatrica

2003

HHV8 è un virus erpetico correlato, sulla base di dati ormai concordi, al sarcoma di Kaposi (KS), al linfoma effusivo primario ed alla Ma- lattia di Castleman multicentrica. Tale virus è stato inoltre associato con altre patologie tumorali ma gli studi in proposito non sono stati confermati. Poco, d’altra parte, si conosce sulle modalità prevalenti di trasmissione del virus, probabilmente diverse nelle nazioni industrializzate ed in quelle in via di sviluppo. In Sicilia una elevata prevalenza del KS clas- sico era già presente in epoca pre-AIDS. Abbiamo condotto uno studio sierologico in immunofluorescenza per rilevare gli anticorpi anti-HHV8 in 40 bambini con leucemia linfoblastica acuta (…

Microbiology (medical)Settore MED/42 - Igiene Generale E ApplicataHuman Herpes virus 8-Leukaemia-Kaposi's sarcoma
researchProduct